Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Genentech, Inc.
Genentech, Inc.
Kahr Medical
Replimune Inc.
ImmunityBio, Inc.
University of Pittsburgh
Gruppo Oncologico del Nord-Ovest
University of Colorado, Denver
Vall d'Hebron Institute of Oncology
Exelixis
Genentech, Inc.
AIO-Studien-gGmbH
University of Texas Southwestern Medical Center
Seattle Project Corporation
University of Iowa
Kahr Medical
Exelixis
Keythera (Suzhou) Pharmaceuticals Co. Ltd
The Netherlands Cancer Institute
Academic and Community Cancer Research United
Hoffmann-La Roche
Amgen
Asan Medical Center
Fate Therapeutics
Federation Francophone de Cancerologie Digestive
Fate Therapeutics
Hoffmann-La Roche
Hoffmann-La Roche
Duke University